JW Lifescience Corporation

KSE 234080.KS

JW Lifescience Corporation Free Cash Flow for the year ending December 31, 2023: USD 22.51 M

JW Lifescience Corporation Free Cash Flow is USD 22.51 M for the year ending December 31, 2023, a 388.26% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

JW Lifescience Corporation Free Cash Flow for the year ending December 31, 2022 was USD 4.61 M, a -48.86% change year over year.
JW Lifescience Corporation Free Cash Flow for the year ending December 31, 2021 was USD 9.01 M, a -67.83% change year over year.
JW Lifescience Corporation Free Cash Flow for the year ending December 31, 2020 was USD 28.01 M, a 104.15% change year over year.
JW Lifescience Corporation Free Cash Flow for the year ending December 31, 2019 was USD 13.72 M, a -39.97% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

KSE: 234080.KS

JW Lifescience Corporation

CEO	Sungnam Cha
IPO Date	Oct. 27, 2016
Location	South Korea
Headquarters	28, Hanjin 1-gil
Employees	301
Sector	Health Care
Industries Pharmaceuticals Biotechnology Water

Description

JW Lifescience Corporation engages in the development, production, and sale of infusion solutions in South Korea and internationally. It offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin, South Korea.

Key trends

Past 5 years